Tag: axial spondyloarthritis (axspa) market outlook

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What Growth Projections are in Place for the Axial Spondyloarthritis (axSpA) Market Between 2024-2033?

In recent years, the market size for axial spondyloarthritis (axspa) has experienced significant growth. It is projected to expand from $5.54 billion in 2023 to $6.04 billion in 2024, representing a compound annual growth rate (CAGR) of 9.0%. This increase during the historical period can be credited to enhancements in diagnostic criteria and biological treatments, heightened awareness of the disease, advances in genetic research, and progress in clinical trials.

The market size for axial spondyloarthritis (axspa) is anticipated to witness robust growth in the coming years. It is projected to escalate to $8.18 billion by 2028, growing at a compound annual growth rate (CAGR) of 7.9%. Contributing factors to this growth during the prediction period involve progress in identifying biomarkers, customized treatments, incorporation of digital health, broader treatment choices, and supportive health policies. Upcoming trends within this duration embrace early interference tactics, care that is integral to the patient, adoption of telemedicine and distant consultations, investigation into disease workings, and collective decision-making.

Claim Your Free Sample of the Global Axial Spondyloarthritis (axSpA) Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp

What Are the Major Factors Contributing to the axial spondyloarthritis (axspa) Market Expansion?

The proliferation of spondyloarthritis is anticipated to fuel the expansion of the axial spondyloarthritis (axSpa) market in the future. Spondyloarthritis is a long-standing ailment primarily targeting the axial skeleton, incorporating the spine and sacroiliac joints. The escalating instances of spondyloarthritis (axSpA) are attributed to the growing elderly population and spinal injuries from even trivial accidents or falls, treating which various methods are applied for pain alleviation, inflammation reduction, and improvement in the quality of life of those affected by axSpA. To illustrate, in June 2023, as per the Musculoskeletal Health Report 2023 by Versus Arthritis, a charity based in the UK devoted to assisting arthritis patients, approximately 60,000 individuals were diagnosed with axial spondyloarthritis in 2022, and nearly 2,200 adults obtain this prognosis annually. Hence, the progressive prevalence of axial spondyloarthritis (axSpa) is influencing the progress of the axial spondyloarthritis (axSpa) market.

Which Key Segments Shape the Axial Spondyloarthritis (axSpA) Market?

1) By Types: Ankylosing spondylitis (AS), Non-radiographic axial spondyloarthritis (nr-axSpA)

2) By Commercialized Therapies: Anti-tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)

3) By Dosage Form: Tablets, Injections

4) By Treatment: Tumor necrosis factor (TNF) Alpha Inhibitors, Non-steroidal anti-inflammatory drugs (NSAID), Conventional Disease Modifying Anti-Rheumatic Drugs, Glucocorticoids, Interleukin Blockers

5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores

What Are the Transformative Trends Influencing the Axial Spondyloarthritis (axSpA) Market?

In the axial spondyloarthritis (axSpA) market, product innovations are emerging as a notable trend. Dominant corporations within the axSpA market are designing new pharmaceuticals to consolidate their market influence. For example, UCB SA, a pharmaceutical firm based in Belgium, was granted marketing authorization from the New European Commission for BIMZELX (bimekizumab) in June 2023. This drug is employed for treating adult patients grappling with active axSpA, non-radiographic axSpA (nr-axSpA), and ankylosing spondylitis (AS), displaying evident inflammation indications such as spiked C-reactive protein. These endorsements from the European Union (EU) mark the first worldwide marketing permissions for this axSpA drug.

Order Now for Fast Delivery of Your Axial Spondyloarthritis (axSpA) Market Report!

https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

What Regions Are Leading the Growth Trajectory of the Axial Spondyloarthritis (axSpA) Market?

North America was the largest region in the axial spondyloarthritis(axSpA) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axspa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Axial Spondyloarthritis (axSpA) Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the axial spondyloarthritis (axspa) market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Axial Spondyloarthritis (axSpA) Market Include

1. Axial Spondyloarthritis (axSpA) Market Executive Summary

2. Axial Spondyloarthritis (axSpA) Market Segments

3. Axial Spondyloarthritis (axSpA) Market Size And Template Market Growth Rate

4. Key Axial Spondyloarthritis (axSpA) Market Trends

5. Major Axial Spondyloarthritis (axSpA) Market Drivers

……

25. Key Mergers And Acquisitions In The Axial Spondyloarthritis (axSpA) Market

26. Top Axial Spondyloarthritis (axSpA) Companies

27. Axial Spondyloarthritis (axSpA) Market Opportunities And Strategies

28. Axial Spondyloarthritis (axSpA) Market, Conclusions And Recommendations

29. Appendix

Discover Related Reports by The Business Research Company:

Arthritis Monoclonal Antibodies Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/arthritis-monoclonal-antibodie-global-market-report

Cervical Spondylosis Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cervical-spondylosis-treatment-global-market-report

TNF Alpha Inhibitors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/tnf-alpha-inhibitor-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

As per The Business Research Company’s Axial Spondyloarthritis (axSpA) Global Market Report 2024, the axial spondyloarthritis (axSpA) market is expected to show significant growth in the forecast period.

The axial spondyloarthritis (axSpA) market has witnessed robust growth in recent years, with promising projections for the future. Key indicators include:

• Market size surged from $5.54 billion in 2023 to $6.04 billion in 2024, exhibiting a Compound Annual Growth Rate (CAGR) of 9.0%.
• Forecast predicts further expansion, reaching $8.18 billion by 2028, with a CAGR of 7.9%.

Drivers of Expansion

Several factors contribute to this growth momentum, including:

• Improved diagnostic criteria facilitating early detection.
• Advancements in biological treatments enhancing therapeutic options.
• Rising disease awareness among healthcare professionals and patients.
• Progress in genetic research shedding light on disease mechanisms.
• Advancements in clinical trials fostering treatment innovation.

View More On The Axial Spondyloarthritis (axSpA) Market Report 2024 – https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report

Rising Prevalence of Axial Spondyloarthritis (axSpA) Fuels Market Growth

Understanding the Landscape

Axial spondyloarthritis (axSpA) is a chronic condition primarily affecting the axial skeleton. Key insights include:

• Increasing prevalence attributed to aging populations and spine injuries.
• Versus Arthritis reports approximately 60,000 cases in the UK, with 2,200 new diagnoses annually.

Key Players Driving Innovation

Leading companies in the axial spondyloarthritis (axSpA) market include:

• Johnson & Johnson Private Limited
• Pfizer Inc.
• Hoffmann-La Roche AG
• Merck & Co. Inc.
• AbbVie Inc.
• Novartis AG
• Sanofi S.A
• Bristol-Myers Squibb Company
• AstraZeneca plc.
• Abbott Laboratories

UCB Sa Secures EU Approval for Bimzelx: A Milestone in Treatment Innovation

Innovative Product Development

Product innovation emerges as a pivotal trend in the market, exemplified by:

• UCB SA’s EU approval for Bimzelx (bimekizumab) in treating axial spondyloarthritis.
• Bimzelx marks a significant advancement in addressing active axSpA and ankylosing spondylitis.

Strategic Partnerships for Enhanced Care

Collaborations drive progress in patient-centric solutions, illustrated by:

• Partnership between Ampersand Health and UCB SA aims to revolutionize axSpA care through digital solutions.
• Integration of digital tools with clinical expertise enhances symptom management and patient outcomes.

Segmentation Insights: Understanding the Market Dynamics

Segmented Analysis

The axial spondyloarthritis (axSpA) market is segmented based on various parameters, including:

• Types: Ankylosing spondylitis (AS), Non-radiographic axial spondyloarthritis (nr-axSpA)
• Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)
• Dosage Form: Tablets, Injections
• Treatment: Tumor necrosis factor (TNF) Alpha Inhibitors, Non-steroidal anti-inflammatory drugs (NSAID), Conventional Disease Modifying Anti-Rheumatic Drugs, Glucocorticoids, Interleukin Blockers
• End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores

Regional Outlook

• North America dominated the market in 2023.
• Asia-Pacific is poised for rapid growth in the forecast period.

Conclusion: Navigating the Future Landscape

The axial spondyloarthritis (axSpA) market presents significant opportunities driven by technological advancements, therapeutic innovations, and strategic collaborations. As the industry embraces early intervention strategies and patient-centric care, the journey towards improved outcomes for axSpA patients continues to evolve, promising a future of enhanced quality of life and better disease management.

Request A Sample Of The Global Axial Spondyloarthritis (axSpA) Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=12590&type=smp